Viber Marks Its Third Birthday By Unveiling Version 4.1 Which Includes The Global Launch Of Viber Out And New Content For Its Sticker Market  

ME NewsWire / Business Wire

LONDON - Tuesday, December 10th 2013
Viber (www.viber.com) announced today the release of Viber 4.1 for Android and iPhone which includes the full global launch of Viber Out, a new feature that allows users to make low-cost calls to any mobile or landline phone number.

Viber had previously enabled Viber Out for users in the Philippines in the aftermath of Typhoon Haiyan to help users contact friends and loved ones. To provide free calls from the Philippines, Viber partnered with telcos across the world including Telecom Austria, Telecom New Zealand, Hutchison, Bharti Airtel, Telecom Italia, Citic, Netvision Cellcom, Mada Communication and Omantel. Viber also partnered with Globe Telecom to allow users worldwide to call the Philippines for free.

Now with the official worldwide launc ... Read more »

The iGrow Hair Growth System is available in more than 38 markets around the world

IRVINE, Calif. - Tuesday, December 10th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Apira Science, Inc. has named China Central Pharmaceuticals Ltd. its exclusive distributor of the iGrow® Hair Growth System in the Chinese market. The partnership highlights Apira’s growing success in the global market, and showcases the burgeoning international demand for a safe and effective hair loss solution. China Central Pharmaceuticals is a 10 billion yuan ($1.6 billion) corporation that houses 28 pharmaceutical subsidiaries and sells more than 20,000 medical products, including 6,000 new drugs, 1,000 medical devices, and 1,800 foreign products throughout China. Through the partnership, the iGrow will be featured in more than 6,000 retail outlets in addition to hospitals and medical facilities throughout China. Within the 33.6 billion yuan ($5.5 billion) Chinese hair care market, sales of Western hair-l ... Read more »

ME Newswire / Business Wire

NEW ORLEANS - Tuesday, December 10th 2013

Median Overall Survival of 40.5 Months in Relapsed/Refractory Hodgkin Lymphoma Patients -

- Estimated Three Year Survival Rate of 63 Percent with Median Overall Survival Not Yet Reached in Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma -

ASH 2013

Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced updated overall survival data from two ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trials in relapsed/refractory Hodgkin lymphoma (R/R HL) and relapsed/refractory systemic anaplastic large cell lymphoma (R/R sALCL) were presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, LA, December 7-10, 2013. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. Median overall survival (OS) of 40.5 months was reported in R/R HL, and was not yet reache ... Read more »

LOS ANGELES - Tuesday, December 10th 2013 [ME NewsWire]

(BUSINESS WIRE)-- MEF GEN14 will define the future of network-enabled cloud, data, and mobile services powered by Carrier Ethernet 2.0, SDN, and virtualization technologies

MEF (Metro Ethernet Forum), the defining body for Carrier Ethernet, launches its industry-wide Global Ethernet Networking (GEN14) conference on November 17-20 2014 at the Gaylord National in Washington, D.C. With a target audience exceeding 1,200 attendees, GEN14 is billed as the must-attend networking event for senior professionals involved in the Carrier Ethernet (CE) services & technology industry that consists of retail, wholesale, and mobile service providers; data center providers; cloud service providers; mid to large businesses; government organizations; network solutions vendors; the press; analysts; and others.

GEN14 (www.gen14.com) will assemble an unprecedented lineup of CE, SDN, NFV, and network-enabled cloud services marke ... Read more »

BASKING RIDGE, N.J - Tuesday, December 10th 2013 [ME NewsWire]


(BUSINESS WIRE) electroCore’s non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st to 24th) and the NANS meeting this weekend (Dec 5th to 8th).

At both meetings there was significant interest in the platform presentations. The gammaCore clinical trial program, including two completed open label studies, as well as their four on-going randomized studies, was discussed in two platform presentations at each meeting.

Following a series of promising open label trials, electroCore is now well underway with the running of the four randomized clinical trials, two of which are being conducted under an US, Investigational Device Exemption (IDE) for both migraine and cluster headaches. The cluster study specifically is a pivotal, double blind, sham controlled study for submissio ... Read more »

− Oral Data Presentation to be Featured in "Highlights of ASH” −

NEW ORLEANS & OSAKA, Japan - Tuesday, December 10th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM). The investigators reported a combined complete response and very good partial response (CR+VGPR) rate of 76 percent (46/62) and a 94 percent overall response rate (ORR; 58/62 ≥ partial response). Stringent complete response (sCR) was reached in 75 percent of patients that attained CR. Overall, drug-related serious adverse events (SAEs) were reported in 28 percent of patients (18/64), and drug-related grade 3 adverse events (AEs) in 58 percent of patients (37/64). There were no drug-related grade 4 AEs. These data were presented today at the 55 ... Read more »

ME Newswire / Businesswire

CORK, Ireland - Monday, December 9th 2013

Lincor Solutions today announced the launch of a new portfolio of products for delivering its industry-leading patient engagement technology to hospitals and health systems. Powered by next-generation technology that provides access to clinical, administrative and entertainment systems within a single platform, Lincor’s LINC product portfolio offers a range of easy-to-implement solutions for increasing patient satisfaction, improving clinical outcomes, reducing unnecessary readmissions and facilitating electronic health record (EHR) adoption.

An increasing international focus on patient satisfaction, readmission rates and maximising the benefits of EHRs has brought patient engagement to the top of hospitals’ agendas.

"Lincor is dedicated to empowering patients by giving them the tools and technology to become engaged in, and informed about, their care. Given the focus on patient satisfactio ... Read more »